Skip to main content
. 2021 Feb 15;18(1):105–119. doi: 10.20892/j.issn.2095-3941.2020.0098

Figure 6.

Figure 6

Schematic model of the role of HBXIP in regulating non-small cell lung cancer (NSCLC). HBXIP promotes NSCLC cell proliferation and tumorigenesis, possibly by activating the MAPK/ERK pathway, and HBXIP stabilizes MEK1 and prevents its degradation by the proteasome pathway.